Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 4/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | SMO | Q99835 | 2/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14545109 | 0.91 | CNR1 (0.52) | CNR1CNR2SMOUSP30PDE10A | |
| SCHEMBL14545727 | 0.84 | CNR1 (0.68) | CNR1CNR2SMOUSP30CYP11B1 | |
| SCHEMBL14545610 | 0.84 | CNR1 (0.69) | CNR1CNR2SMOPDE10AHCRTR1 | |
| SCHEMBL14545499 | 0.83 | CNR1 (0.53) | CNR1CNR2SMOHCRTR1HCRTR2 | |
| SCHEMBL14545732 | 0.82 | CNR1 (0.73) | CNR1CNR2SMOMAPK11MAPK14 | |
| SCHEMBL14545729 | 0.81 | CNR1 (0.49) | CNR1CNR2SMOUSP30HCRTR1 | |
| SCHEMBL14545482 | 0.81 | CNR1 (0.60) | CNR1CNR2SMOUSP30CYP11B1 | |
| SCHEMBL14545505 | 0.81 | CNR1 (0.54) | CNR1CNR2SMOUSP30 | |
| SCHEMBL14545753 | 0.81 | CNR1 (0.54) | CNR1CNR2SMOUSP30HCRTR1 | |
| SCHEMBL14545712 | 0.80 | CNR1 (0.46) | CNR1CNR2SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | NEUROGEN CORPORATION (US) | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078135-A1 | Substituted heteroaryl CB1 antagonists | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885SMO 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.